StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research report released on Thursday morning. The firm issued a hold rating on the stock.
Separately, HC Wainwright dropped their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research note on Monday, August 12th.
Check Out Our Latest Report on ONCT
Oncternal Therapeutics Trading Down 2.4 %
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. During the same quarter last year, the firm posted ($3.00) EPS. As a group, research analysts forecast that Oncternal Therapeutics will post -11.63 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned about 0.94% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by institutional investors.
Oncternal Therapeutics Company Profile
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Read More
- Five stocks we like better than Oncternal Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What Makes a Stock a Good Dividend Stock?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Top Stocks Investing in 5G Technology
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.